Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Sintilimab in Follicular Lymphoma: NCT07077512 Clinical Landscape Report 2026
28 September 2026
NCT07077512 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SONALA-001 in Glioblastoma Multiforme: NCT07076472 Clinical Landscape Report 2026
28 September 2026
NCT07076472 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SC-101 in Hormone receptor positive breast cancer: NCT07080619 Clinical Landscape Report 2026
28 September 2026
NCT07080619 clinical landscape for Hormone receptor positive breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Zeprumetostat in High grade B-cell lymphoma: NCT07082803 Clinical Landscape Report 2026
28 September 2026
NCT07082803 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[18F]DCFPyL in Renal Cell Carcinoma: NCT07084909 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_02_0815c5db75.jpg)
9 min read
[18F]DCFPyL in Renal Cell Carcinoma: NCT07084909 Clinical Landscape Report 2026
28 September 2026
NCT07084909 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IBR854 in Advanced Renal Cell Carcinoma: NCT07087158 Clinical Landscape Report 2026
28 September 2026
NCT07087158 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant oncolytic virus M1(Guangzhou Vitron) in Glioblastoma: NCT07093814 Clinical Landscape Report 2026
28 September 2026
NCT07093814 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etoposide in High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: NCT07097363 Clinical Landscape Report 2026
28 September 2026
NCT07097363 clinical landscape for High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: endpoints, sponsor, phase, geography, readouts, a…
9 min read
ERAS-801 in Gliosarcoma: NCT07089641 Clinical Landscape Report 2026
28 September 2026
NCT07089641 clinical landscape for Gliosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
tanCART-19/22 cells(Chinese PLA General Hospital) in High grade B-cell lymphoma: NCT07094477 Clinical Landscape Report 2026
28 September 2026
NCT07094477 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pazopanib Hydrochloride in Renal Cell Carcinoma: ACTRN12625000814471 Clinical Landscape Report 2026
28 September 2026
ACTRN12625000814471 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vevoctadekin in Refractory Indolent Non-Hodgkin Lymphoma: NCT07098364 Clinical Landscape Report 2026
28 September 2026
NCT07098364 clinical landscape for Refractory Indolent Non-Hodgkin Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development wh…